Functionally, VitD3 and the EB-1089 analogue can reduce growth, inhibit MYC expression and increase CD38 expression by 50-400% on ABC-DLBCL and myeloma but not GC-DLBCL cells. This evidence concerns the gene MYC and plasma cell myeloma.